ABSTRACT. Carnitine and acylcarnitines were measured in plasma and tissues of control turkeys, turkeys with an inbred spontaneous cardiomyopathy, and turkeys with furazolidone-induced cardiomyopathy. Heart failure was evident in both types of cardiomyopathy from decreased systemic blood pressure and cardiac dilatation compared to controls. Plasma free carnitine, short-chain acylcarnitine, and long-chain acylcarnitine were significantly elevated by 76 to 614% (p < 0.01) in the two cardiomyopathy models compared to control. The highest carnitine levels were found in the most hypotensive turkeys. Liver free carnitine and short-chain acylcarnitine levels were also elevated by 45 to 537% (p < 0.05) in both types of cardiomyopathy. The present report describes alterations in carnitine and acylcarnitines in plasma and tissues of domestic turkeys with congestive cardiomyopathy. Two distinct types of turkey cardiomyopathy were investigated. The first is a SC preserved in an inbred flock. At 2 months of age, greater than 70% of the turkeys have marked cardiac dilatation, involving predominantly the left ventricle. Their congestive cardiomyopathy has been previously characterized with respect to histopathology (23), hemodynamics (lo), cellular electrophysiological changes (9), regional myocardial blood flow (1 1), cardiac nucleoproteins (17, 18), and altered sarcoplasmic reticulum function (33). Although the etiology of this cardiomyopathy is not precisely known, and may be viral in origin (23), recently demonstrated nucleoprotein phosphorylation changes suggest a genetic etiology (1 7, 18).
The present report describes alterations in carnitine and acylcarnitines in plasma and tissues of domestic turkeys with congestive cardiomyopathy. Two distinct types of turkey cardiomyopathy were investigated. The first is a SC preserved in an inbred flock. At 2 months of age, greater than 70% of the turkeys have marked cardiac dilatation, involving predominantly the left ventricle. Their congestive cardiomyopathy has been previously characterized with respect to histopathology (23) , hemodynamics (lo), cellular electrophysiological changes (9), regional myocardial blood flow (1 1), cardiac nucleoproteins (17, 18) , and altered sarcoplasmic reticulum function (33) . Although the etiology of this cardiomyopathy is not precisely known, and may be viral in origin (23) , recently demonstrated nucleoprotein phosphorylation changes suggest a genetic etiology (1 7, 18) .
The second type is a FC associated with ingestion of furazolidone, a nitrofuran antibiotic used for prophylaxis and treatment of gram-negative bacterial disease of turkeys (6, 7, 15, 32) . This cardiomyopathy may result from furazolidone interference with the conversion of pyruvate to acetyl CoA (7, 13, 32) . To produce this cardiomyopathy, normal turkeys receive furazolidone in their feed continuously from hatching onward. At the age of 2 months, left ventricular dilatation, systemic hypotension, congestive cardiomyopathy, and hepatic dysfunction are present (6, 18, 32) .
The present study reveals that turkeys with both types of cardiomyopathy have elevated plasma free carnitine and acylcarnitines as well as increased carnitine levels in some tissues. The most striking alterations in carnitine levels are present in turkeys with the most severe cardiomyopathy and hemodynamic derangements.
Carnitine, 3-hydroxy-4-N-trimethylaminobutyric acid, is an essential cofactor for transport of long-chain fatty acids across the inner mitochondria1 membrane. Since long-chain fatty acids are a preferred energy substrate of cardiac tissue, (22, 38) alterations in carnitine metabolism may contribute to the pathogenesis of cardiac dysfunction in cardiomyopathy. Tissue carnitine deficiency has been documented in humans with endocardia1 fibroelastosis (36), humans with congestive cardiomyopathy (39), dystrophic cardiomyopathic hamsters (2) , and rats with pressureoverload myocardial hypertrophy (28) . Plasma (or serum) carnitine has been reported as low (36, 39) , elevated (37), or normal (8, 28) in altered myocardial states. In addition, diabetes (31), fasting (2 l),and myocardial ischemia (14, 29) are associated with alterations in liver and heart carnitine levels.
Broad-breasted white turkeys (Nicholas) for controls were obtained from a commercial hatchery (Barron, WI) as newly hatched poults or as fertile eggs. SC turkeys were obtained from random breeding of an inbred flock maintained at the Minneapolis Medical Research Foundation facility, Cokato, MN. All eggs were incubated in a Petersime incubator at 37.5" C until hatching. Control turkeys and SC turkeys were fed the University of Minnesota Veterinary School Turkey Ration no. 1 which provides 546 callkg of feed and contains 28% protein, 2.3% fat, 3% fiber, and supplemental vitamins and minerals.
To produce the group of turkeys with FC cardiomyopathy, normal (Nicholas) turkeys were fed the University of Minnesota Turkey Ration no. 1 with added furazolidone (0.5 g/kg feed) from hatching onward (32) . The furazolidone was discontinued 24 h prior to study. All turkeys were allowed free access to feed and water until immediately before study and sacrifice. artery using local xylocaine anesthesia. Arterial pressure measurements were made using fluid-filled catheters attached to Statham P23Db strain gauges. A lead I1 electrocardiogram was simultaneously recorded on an Electronics for Medicine multichannel recorder at a paper speed of 100 mm/s. The preejection period was measured from the onset of the QRS to the upstroke of the arterial pressure; the left ventricular ejection time was measured from the upstroke of the arterial pressure to the dicrotic notch. The measurements were made (average 5-8 beats) with a Numonics Graphics Analyzer (model 1238). The ratio PEP/ LVET, calculated for some turkeys, is an indication of ventricular contractility ( 18) .
Extraction offree carnitine and acylcarnitine. Before sacrifice, the turkeys were weighed, heparinized (300 U/kg), and arterial blood was withdrawn and placed at 4" C. Plasma was then removed by centrifugation at 4" C. The turkeys were anesthetized with 20 mg/kg sodium thiopental. The hearts were rapidly removed and weighed after atria were trimmed off. Measurements for a dilation index were taken and the tissue immediately frozen on dry ice for later assay. The dilation index is the ratio of the transverse diameter of the left ventricular cavity to the transverse diameter of the left ventricular chamber (cavity plus lateral wall and interventricular septum) (17) . Livers and skeletal muscle (red muscle) were frozen immediately and stored at -60" C. After rinsing in cold 0.9% saline, tissue homogenates were prepared from 50-100 mg of left ventricular apex, liver, and skeletal muscle by finely mincing in ice-cold distilled water and homogenization twice in a Polytron PT-20 at a rheostat setting of 10 for 15 s with a 30 s cooling period in between. Aliquots from each tissue homogenate were removed for measurement of noncollagenous protein by the method of Lowry et al. (19) using bovine serum albumin as a standard.
Using modifications (8, 26) of the procedure of Pearson et al. (25) , carnitine from tissues and plasma was separated into free carnitine, short-chain acylcarnitine, and long-chain acylcarnitine. Long-chain acylcarnitine was precipitated from turkey tissue homogenates with perchloric acid (0.6 M). The centrifuged pellet was washed with perchloric acid and recentrifuged. The pellet was incubated in 1 N KOH for 2 h at 50" C. Following neutralization with 1 N HCl, precipitation on ice and centrifugation, the supernatant was assayed for carnitine as described below.
The initial supernatant fractions of the first perchloric acid treatment were neutralized with 4 N KOH, precipitated on ice, and centrifuged. The resulting supernatant fraction was assayed for free carnitine by the method described below. Short-chain acylcarnitines are also acid soluble, so aliquots of the supernatant fraction were treated with 1 N KOH, incubated at 50" C for 1 h, and neutralized by 1 N HCl. The resulting solution was assayed for carnitine and is a combined measure of free carnitine and short-chain acylcarnitine.
Carnitine assay. Carnitine was assayed in the prepared tissue and plasma extracts by modifications of the methods of McGany and Foster (20) and Parvin and Pande (24), using L-carnitine as a standard. Duplicate aliquots of extract were added to a reaction mixture (0.55 ml) containing 50 mM HEPES-KOH buffer pH 7.6, 0.25 mM N-ethyl-maleimide (NEM), and 0.01 rCi [I-I4C] acetyl coenzyme A (New England Nuclear, Boston, MA). The reaction was initiated by the addition of 0.5 U carnitine acetyltransferase (Sigma, St. Louis, MO) followed by frequent mixing at 25" C for 30 min. The reaction was terminated by the addition of charcoal in acidified alcohol (24), followed by equilibration on ice for 30 min. After centrifugation, an aliquot of the supernatant fraction was placed in scintillation fluid and radioactivity counted. In this assay, standard linear curves for L-carnitine were generated from 20-200 pmol carnitinelm1 reaction mixture. Recovery of added L-carnitine (5.25 nmol/ml) to turkey plasma was 97%, while recovery of added L-carnitine to extracted turkey plasma was 99%.
Statistical analysis. Standard statistical methods including two-tailed Student's t test for unpaired samples, Welch-Aspin test (when sample variability dictated its use), and least squares linear regression analysis were used in data analysis. Results are considered significant for p < 0.05.
RESULTS
Two-month-old turkeys from the spontaneous cardiomyopathy flock and from the group which received furazolidone all had evidence of cardiomyopathy. They all had decreased mean blood pressures (Fig. I) , decreased systolic and diastolic blood pressures, as well as cardiac dilation compared to control turkeys (Table 1) (17, 18) .
Both types of cardiomyopathic turkeys (SC and FC) had a significantly lower body weight, which has previously been observed (17, 18) and may be attributable to reduced growth secondary to cardiac dysfunction. The heart weightbody weight ratio of the FC turkeys was increased (Table 1) compared to controls as has been documented previously for this type of turkey (18) . Due to marked variation in the degree of cardiac dilatation among SC turkeys, there was no statistically significant difference in heart weightbody weight ratios when compared with controls (1 8 Measurements of carnitine indicated that the cardiomyopathic turkeys (both SC and FC) had significantly elevated plasma levels of free carnitine, short-chain acylcarnitine, and long-chain acylcarnitine compared to controls (Fig. 2) . Furthermore, there was a significant inverse correlation between elevated plasma levels of free carnitine and the degree of cardiac compromise evidenced by hypotension (Fig. 3) . The highest plasma free carnitine levels were measured in FC turkeys and these same turkeys had the lowest mean systemic blood pressures (Fig. 3) . Turkeys with SC cardiomyopathy had intermediate plasma levels of free carnitine and less reduction in blood pressure. Lastly, the lowest plasma Numbers in parentheses represent the number of animals. C, controls. * p < 0.001; t p < 0.01. Fig. 3 . Least squares linear regression analysis of the relationship between plasma free carnitine and mean blood pressure. 0, furazolidoneinduced cardiomyopathy, n = 6; A, spontaneous cardiomyopathy, n = 7; o, control, n = 6. free carnitine was found in the control turkeys who have the highest (normal) mean blood pressures. Similar inverse relationships exist for mean blood pressure and either plasma shortchain acylcarnitine or plasma long-chain acylcarnitine (not depicted).
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Cardiomyopathic turkeys did not have tissue free carnitine or acylcarnitine deficiency. On the contrary, FC turkeys had significantly elevated left ventricular myocardial levels of free carnitine and short-chain acylcarnitine (Fig. 4) . Skeletal muscle free carnitine was elevated (p < 0.05) in FC turkeys (441 + 42 nmol/ 100 mg noncollagenous protein versus 286 + 23 for control and 323 + 56 for SC turkeys). Skeletal muscle short-and long-chain acylcarnitines in the SC and FC turkeys were similar to control values of 98 + 7 and 7.4 + 3 nmo1/100 mg noncollagenous protein, respectively. Finally, liver free carnitine and short-chain acylcarnitine were significantly elevated in both SC and FC turkeys (Fig. 5) . Liver long-chain acylcarnitine was elevated in SC turkeys but not FC turkeys (Fig. 5) .
DISCUSSION
This study was performed to investigate whether any alteration in carnitine metabolism is present in two turkey models of congestive cardiomyopathy. Since congestive cardiomyopathy and myocardial dysfunction have previously been associated with carnitine deficiency (2, 28, 36, 39) , the hypothesis tested by our study was that turkeys with spontaneous cardiomyopathy had carnitine deficiency and that this might be different from turkeys with furazolidone cardiomyopathy.
The major findings of this study are that plasma levels of free carnitine as well as short-chain acylcarnitine and long-chain acylcarnitine are markedly elevated in both types of turkey cardiomyopathy and, furthermore, the highest plasma carnitine levels are present in the most hypotensive turkeys (FC). In addition, liver free carnitine and short-chain acylcarnitine are elevated in both types of turkey cardiomyopathy. The most hypotensive turkeys (FC) also had the highest liver free carnitine and acylcarnitine, while the elevated liver carnitine levels were not as high in the less hypotensive SC turkeys. Since the liver is a site of carnitine biosynthesis, the plasma and liver carnitine elevations suggest the possibility of increased liver carnitine biosynthesis, perhaps as a response to progressive cardiac failure. Diabetes and fasting (2 1) are two factors which can elevate liver free and total carnitine levels (presumably by biosynthesis). These conditions were not present in the turkeys utilized in these experiments, since no turkey was deprived of water or feed. We cannot completely exclude a discrepancy in oral intake over the 2 months of study between cardiomyopathic and normal turkeys since we did not measure total feed intake. However, our close monitoring of these turkeys during the study period indicated to us that all turkeys had equal access to water and feed. The body weights of both types of cardiomyopathic turkeys were very similar, yet the liver free carnitine of the FC turkeys was approximately three times higher than SC turkeys (Fig. 5) , suggesting that poor oral intake alone cannot account for this difference. Free carnitine and short-chain acylcarnitine are significantly higher in left ventricular tissue of FC turkeys than in control or SC turkeys. Since it is generally accepted that cardiac tissue cannot synthesize carnitine, this may reflect increased or stimulated transport of free carnitine into myocardial cells because of increased availability of carnitine in plasma. The differences in plasma and tissue levels of carnitine between the two types of turkey cardiomyopathy may suggest different etiologies for each type or, more likely, it may reflect the fact that the FC turkeys of our study were in a more advanced state of myocardial decompensation compared to the SC turkeys.
Other conditions causing myocardial dysfunction are known to be associated with marked alterations in carnitine and long chain fatty acid metabolism. Myocardial ischemia with reduced cardiac function is associated with increased myocardial longchain acyl CoA, increased long-chain acylcarnitines, as well as decreased acetyl CoA, short-chain acylcarnitine, free coenzyme A, and free carnitine (14, 35, 40) . Increased long-chain acyl CoA may inhibit important membrane systems such as adenine nucleotide translocase (29) , carnitine palmityl CoA transferase (3), and Na+, K+ ATPase of sarcolemma (41) . Similarly long-chain acylcarnitine can interfere with Na+, K+ ATPase, K+ phosphatase (41) , and calcium binding in the sarcoplasmic reticulum (1). Replacement of carnitine may be of benefit in ischemic hearts (12, 16) , since it has been demonstrated that such supplementation resulted in more stable cardiac electrical activity, increased tissue high energy phosphates, and restored adenine nucleotide translocase activity (12) . Furthermore, carnitine supplementation has been associated with decreased incidence of heart failure in humans with diphtheria (27) , improved survival of diphtheric guinea pigs (9, and improved survival of mice treated with doxorubicin (34) . Myocardial carnitine levels have been reported as reduced in diphtheric guinea pigs (4), and reduced, but not significantly, in doxorubicin-treated mice (34) . It is unclear whether the improved survival in either species is related to normalization of myocardial carnitine.
The effect of carnitine supplementation on mortality and develovment of cardiac dilation has vet to be determined in these two types of cardiomyopathic turkeys. However, propranolol therapy has been associated with reduced cardiac dilation in furazolidone-supplemented turkeys (13) , suggesting that it is valuable to decrease B-adrenergic drive in these turkeys. Whether the administration of propran~lol could also prevent the increase in plasma and tissue carnitines in FC cardiomyopathy is not yet known.
It is interesting to compare the elevated carnitines of these two turkey cardi~mfo~athies with the fact that some humans with severe congestive cardiomyopathy have elevated plasma carnitine levels (37) . It is possible that carnitine metabolism is altered in humans in a manner analogous to our turkeys. Furthermore, this study suggests that myocardial failure influences the regulation of plasma levels of free carnitine and acylcarnitine. In response to hypotension and decreased cardiac output, hepatic biosynthesis of carnitine may be stimulated. This potentially useful increased availability of carnitine to combine with longchain fatty acids may shift the balance toward more @-oxidation of fatty acids and thus provide the heart and tissues with greater energy supply.
Alternatively, since carnitine is removed from plasma by renal excretion, the data presented here are also consistent with the hypothesis that the increased plasma and tissue carnitine levels are due to decreased renal excretion. Cardiac failure may impair renal function by reducing renal blood flow and, thus reducing carnitine excretion. However, previous measurements of renal arterial blood flow in turkeys with SC cardiomyopathy have revealed no significant differences compared to control turkeys (1 1). Renal blood flow measurements have not yet been made in FC turkeys. Urinary carnitine excretion measurements as well as studies of fatty acid oxidation rates will be informative to define more clearly the mechanisms responsible for the carnitine alterations reported herein.
